Relapsed 6q24-related transient neonatal diabetes mellitus successfully treated with sulfonylurea

@article{Fu2019Relapsed6T,
  title={Relapsed 6q24-related transient neonatal diabetes mellitus successfully treated with sulfonylurea},
  author={Jun Fu and Tong Wang and Xin-Hua Xiao},
  journal={Chinese Medical Journal},
  year={2019},
  volume={132},
  pages={846 - 848},
  url={https://api.semanticscholar.org/CorpusID:85447731}
}
A Chinese male patient with a history of 6q24-related TNDM (hypomethylation of the maternal allele) who relapsed at 14 years old and was successfully treated with a low dose of glimepiride is reported.
View on PubMed
doi.org
12 Citations
Background Citations
3

12 Citations

Successful Transition to Sulfonylurea for Relapsed Monogenic Diabetes Due to Rare 6q23.3 Duplication

The first report to the authors' knowledge of TNDM secondary to a rare 6q23.3 duplication for which reemergence of diabetes was successfully transitioned from insulin to SU treatment, which improved glycemic control, cost-effectiveness, and overall quality of life, while decreasing occurrence of hypoglycemia.

Severe Dental Disease as a Presenting Sign of Relapsed 6q24-Related Transient Neonatal Diabetes Mellitus

A case of an adolescent female with TNDM due to 6q24 hypomethylation who relapsed at 15 years of age with severe dental disease as the presenting sign is described.

Monogenic diabetes: recent updates on diagnosis and precision treatment: A narrative review

The distinct etiology and subgroups that contribute to predicting and treating clinical phenotypes associated with monogenic diabetes are discussed and methods of prioritizing patient screening for genetic testing are suggested.

Monogenic diabetes: a gateway to precision medicine in diabetes.

The types of monogenic diabetes are described, including common and uncommon types of maturity-onset diabetes of the young, multiple causes of neonatal DM, and syndromic diabetes such as Wolfram syndrome and lipodystrophy.

Systematic Review of Treatment of Beta-Cell Monogenic Diabetes

There is limited evidence to guide the treatment in monogenic diabetes with most studies being non-randomized and small.

Clinical features and partial proportional molecular genetics in neonatal diabetes mellitus: a retrospective analysis in southwestern China

The clinical manifestations and treatment regimens of patients with NDM vary according to the type of gene mutation, and even the same mutant genotype has differences in phenotype and response to treatment.

Do second generation sequencing techniques identify documented genetic markers for neonatal diabetes mellitus?

Wolcott-Rallison Syndrome, a Rare Cause of Permanent Diabetes Mellitus in Infants—Case Report

The case of a 2-month-old infant with extreme hyperglycemia and severe diabetic ketoacidosis is illustrated, illustrating both the therapeutic success of subcutaneous insulin therapy and the ongoing complications that patients with Wolcott-Rallison syndrome are subject to.

Transient Neonatal Diabetes Mellitus Managed with Continuous Subcutaneous Insulin Infusion (CSII) and Continuous Glucose Monitoring

A term newborn who showed overt progression of transient neonatal diabetes mellitus, with complete remission within 6 months, is presented, involving a case involving a term newborn with persistent hyperglycemia.

Neonatal carbohydrate metabolism disorders: a personalized approach to diagnostics and treatment

    I. Alimova
    Medicine
    Rossiyskiy Vestnik Perinatologii i Pediatrii…
  • 2020
It is shown that the introduction into clinical practice of the principles of the personalized medicine contributed to improving the quality of medical care for newborns with endocrine diseases and substantiated the directions for the further development of neonatal endocrinology.

6 References

Chromosome 6q24-related diabetes mellitus

6q24-related diabetes should be considered as one of the differential diagnoses for patients with MODY-like diabetes, especially when they are SGA at birth, especially if they are non-obese patients who are autoantibody negative.

Relapsing 6q24‐related transient neonatal diabetes mellitus successfully treated with a dipeptidyl peptidase‐4 inhibitor: a case report

Treatment of relapsed 6q24‐related TNDM with a DPP4 inhibitor targeting the GLP1 pathway can be a useful alternative because these patients retain the β cell mass and responsiveness through G protein‐coupled pathways.

Successful off‐label sulfonylurea treatment of neonatal diabetes mellitus due to chromosome 6 abnormalities

Oral sulfonylurea therapy seems effective and safe in chromosome 6‐related TNDM treatment when used to treat the initial episode of diabetes or the relapse, and improves patients’ and families’ quality of life.

Sulfonylurea in the treatment of neonatal diabetes mellitus children with heterogeneous genetic backgrounds

It was showed that SU monotherapy resulted in satisfactory glycemic control in most of the patients with NDM whose genetic defects are heterogeneous, and the usage of SU may be considered as first-line therapy for patients withNDM in developing countries where effective genetic screening is not established.

Neonatal diabetes mellitus: A model for personalized medicine